Pharmacy Buying Association, Inc.

Pharmacy Buying Association, Inc., doing business as PBA Health, is a Kansas City, Missouri-based for-profit small business that supplies pharmaceutical products and medical/surgical supplies to the Department of Veterans Affairs as a prime contractor (100% of recent awards), competing predominantly under total small business set-asides across a fragmented portfolio of 1,543 purchase orders and delivery orders to VA Veterans Health Administration networks.

PBA Health's federal footprint is entirely concentrated on VA pharmacy distribution. The vendor operates through two tiers of contract vehicles: a network of single-award indefinite delivery contracts (IDCs) with individual VA VISNs (Veterans Integrated Service Networks), each typically valued between $382 thousand and $2.1 million, and a $15.6 million multiple-award Federal Supply Schedule contract for pharmaceuticals and drugs. Recent representative work includes a $2.18 million firm fixed-price purchase order from VISN 15 in February 2026 for Duloxetine HCL capsules in three dosage strengths delivered to multiple Consolidated Mail Outpatient Pharmacies (CMOPs); a $827.751 million order from VISN 15 in June 2025 for Ibuprofen tablets in multiple strengths (400mg, 600mg, and 800mg) to eight CMOP locations; and a $2.075 billion unrestricted purchase order from VISN 15 in February 2024 for Tamsulosin HCL capsules distributed to national CMOP locations. Smaller orders typical of the portfolio run between $5 thousand and $300 thousand per line item, covering individual pharmaceutical SKUs or multi-line lots of medications (thyroid, antibiotics, ophthalmics, diabetes treatments, pain management, and medical/surgical supplies such as insulin pump reservoirs and diagnostic devices) to regional CMOP facilities.

Customer concentration is extreme and sustained. VISN 15 (Kansas City region) represents 45% of all awards (695 of 1,543) and 64% of combined potential value ($108.3 million of $169.5 million), anchoring the portfolio. The top five VISNs account for 78% of award count and 93% of potential value by dollar magnitude. VISN 12 (Hines, Illinois area) ranks second by dollar value at $23.1 million across 99 awards, despite trailing VISN 7 (164 awards) in volume. This concentration reflects PBA Health's role as a regional primary vendor for VISN 15 with subsidiary relationships across other networks, all under the VA pharmacy distribution model. Award velocity has declined sharply: 81 awards in 2022 falling to 6 awards year-to-date in 2026, signaling either contract consolidation within the VA's CMOP procurement or loss of work to competitors.

PBA Health holds parent contract vehicles through the VA's multiple-award Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs, placing 87 task orders worth $3.4 million in combined potential value, and several named single-award IDCs specific to VISN 15 and other networks (VA NCO 15 Valproic Acid 2016-2021, Indefinite Delivery Contracts 36C77019D0004, VA77017D0001, and VA25514D0107 carrying smaller task order values). The vendor competes exclusively under total small business set-asides on a significant portion of recent awards, though a growing share of larger pharmaceutical orders ($500 thousand to $4.6 million) are competed on a full-and-open, unrestricted basis.

Set-aside posture splits between total small business designations (which dominate smaller orders) and unrestricted competition (anchoring the largest single line items). Across the portfolio, NAICS 325412 (Pharmaceutical Preparation Manufacturing) accounts for 1,245 of 1,543 awards, with PSC 6505 (Drugs and Biologicals) dominating procurement coding. The vendor's competitive model appears commodity-driven: no specialized capability differentiation is evident from award titles; competition turns on ability to source, warehouse, and deliver specific pharmaceutical SKUs within 10-day delivery windows to distributed CMOP nodes, compliance with Drug Supply Chain Security Act documentation, and state wholesale distributor licensing. Recompete exposure over the next 24 months is minimal—only one award ($36 thousand) reaches ultimate completion inside that window—but the sharp drop in annual award count (from 81 in 2022 to 6 in 2026) suggests the underlying parent contracts are either sunsetting, consolidating, or being displaced by larger prime vendor arrangements.

PBA Health is a distributor of pharmaceutical products and a provider of various services to retail pharmacies.